Skip to content

Nicollette Thornton

Central Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; ARC Centre of Excellence for Children and Families over the Life Course, Australia.

2 papers in the library · 17 citations · publishing 2023-2025

Papers

A systematic review of the print media representation of ketamine treatments for psychiatric disorders

BJPsych Open June 7, 2023 Nicollette Thornton, Jason Kawalsky, Alyssa Milton et al. 11 citations

A systematic review of 119 print and online news articles from 2015 to 2020 found that media coverage of ketamine for psychiatric disorders was extremely positive (68.9% of articles). The rapid antidepressant effect was frequently emphasized (73.1% of articles), while longer-term safety and efficacy received little attention. Side-effects were reported in 80.7% of articles, mainly acute psychotomimetic effects and addiction risk, but rarely cardiovascular or bladder effects. Key opinion leaders, such as clinicians, often provided overly optimistic quotes that went beyond the existing evidence base. The authors conclude that information shaping patient expectations is being communicated through the media, and clinicians should address patients' beliefs directly.

Safety outcomes of ketamine for treatment-resistant depression in clinical settings and development of the ketamine side effect tool-revised (KSET-R).

Psychiatry research February 1, 2025 Adam Bayes, Thanh Vinh Cao, Ana Rita Barreiros et al. 6 citations

Ketamine and its derivatives are increasingly used for treatment-resistant depression, but they can cause side effects during and between treatment sessions. The Ketamine Side Effect Tool (KSET) was designed to monitor these effects, but its length limited its use in clinics. Using retrospective data from three outpatient services, researchers calculated how often side effects occurred within sessions, between sessions, and at follow-up. They then developed a shorter version, the KSET-Revised (KSET-R), which showed good construct and concurrent validity for specific items and an overall tolerability rating. The revised tool is more feasible for clinical practice and is recommended for monitoring side effects in patients receiving ketamine treatment.